Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Certara, Inc.

In a report released today, Heiko Ihle from H.C. Wainwright maintained a Buy rating on Cerrado Gold, with a price target of C$3.90. According to Ti...

H.C. Wainwright Keeps Their Buy Rating on Cerrado Gold (CRDOF)

Cerrado Gold ( ($TSE:CERT) ) just unveiled an announcement. Cerrado Gold Inc., a Toronto-based precious and base metals producer and developer, ope...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CERT	$9.11	+2.47%	2.82M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CERT	$9.11	+2.5%	2.82M
3
4
5
6

CERT

Get Certara, Inc. Data in Excel

Get Certara, Inc. Data in Excel